KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-Current Deffered Revenue (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Non-Current Deffered Revenue for 11 consecutive years, with $12.3 million as the latest value for Q3 2025.

  • Quarterly Non-Current Deffered Revenue changed 0.0% to $12.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $12.3 million through Sep 2025, changed 0.0% year-over-year, with the annual reading at $12.3 million for FY2024, 12.05% down from the prior year.
  • Non-Current Deffered Revenue hit $12.3 million in Q3 2025 for CRISPR Therapeutics AG, roughly flat from $12.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $15.8 million in Q3 2023 to a low of $11.8 million in Q2 2021.
  • Historically, Non-Current Deffered Revenue has averaged $12.6 million across 5 years, with a median of $12.3 million in 2021.
  • Biggest five-year swings in Non-Current Deffered Revenue: increased 28.4% in 2023 and later fell 22.12% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $12.3 million in 2021, then changed by 0.0% to $12.3 million in 2022, then increased by 13.71% to $14.0 million in 2023, then fell by 12.05% to $12.3 million in 2024, then changed by 0.0% to $12.3 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for CRSP at $12.3 million in Q3 2025, $12.3 million in Q2 2025, and $12.3 million in Q1 2025.